

Elizabeth Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3297697/publications.pdf>

Version: 2024-02-01

36
papers

3,974
citations

257357

24
h-index

377752

34
g-index

38
all docs

38
docs citations

38
times ranked

3754
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid evaluation of the safety of COVID-19 vaccines: how well have we done?. <i>Clinical Microbiology and Infection</i> , 2022, 28, 477-478.	2.8	6
2	Inference of the SARS-CoV-2 generation time using UK household data. <i>ELife</i> , 2022, 11, .	2.8	40
3	Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 603-610.	4.6	154
4	Predicting the efficacy of new coronavirus vaccines – Are neutralising antibodies enough?. <i>EBioMedicine</i> , 2022, 79, 104034.	2.7	0
5	Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America. <i>Vaccine</i> , 2021, 39, 1551-1555.	1.7	7
6	Impact of COVID-19 social distancing measures on future incidence of invasive pneumococcal disease in England and Wales: a mathematical modelling study. <i>BMJ Open</i> , 2021, 11, e045380.	0.8	15
7	Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. <i>Journal of Infection</i> , 2021, 83, 483-489.	1.7	37
8	Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy. <i>CNS Drugs</i> , 2020, 34, 1-8.	2.7	21
9	Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing. <i>Vaccine</i> , 2020, 38, 7834-7841.	1.7	0
10	Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study. <i>PLoS Medicine</i> , 2020, 17, e1003225.	3.9	6
11	Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: An ecological study. <i>Vaccine</i> , 2020, 38, 4816-4819.	1.7	6
12	Pneumococcal pneumonia. <i>Thorax</i> , 2020, 75, 6-7.	2.7	7
13	Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study. <i>PLoS Medicine</i> , 2019, 16, e1002845.	3.9	34
14	Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. <i>Biologicals</i> , 2019, 60, 1-7.	0.5	18
15	Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 441-451.	4.6	403
16	Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. <i>BMC Medicine</i> , 2018, 16, 13.	2.3	76
17	Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1+1) compared with two primary doses and a booster (2+1) in UK infants: a multicentre, parallel group randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 171-179.	4.6	97
18	Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. <i>PLoS ONE</i> , 2018, 13, e0195799.	1.1	80

#	ARTICLE	IF	CITATIONS
19	Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England. <i>Sleep</i> , 2016, 39, 1051-1057.	0.6	44
20	The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. <i>PLoS Medicine</i> , 2015, 12, e1001839.	3.9	66
21	Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 535-543.	4.6	474
22	Invasive Pneumococcal Disease, Comorbidities, and Polysaccharide Vaccine Use in Children Aged 5-15 Years in England and Wales. <i>Clinical Infectious Diseases</i> , 2014, 58, 517-525.	2.9	17
23	Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 839-846.	4.6	416
24	Influenza and RSV make a modest contribution to invasive pneumococcal disease incidence in the UK. <i>Journal of Infection</i> , 2013, 66, 512-520.	1.7	26
25	Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. <i>BMJ</i> , The, 2013, 346, f794-f794.	3.0	254
26	The impact of specific and non-specific immunity on the ecology of <i>Streptococcus pneumoniae</i> and the implications for vaccination. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2013, 280, 20131939.	1.2	29
27	The Social Life of Infants in the Context of Infectious Disease Transmission; Social Contacts and Mixing Patterns of the Very Young. <i>PLoS ONE</i> , 2013, 8, e76180.	1.1	49
28	Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. <i>Vaccine</i> , 2012, 30, 6802-6808.	1.7	190
29	Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales. <i>PLoS ONE</i> , 2012, 7, e39927.	1.1	41
30	Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 760-768.	4.6	572
31	Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales. <i>PLoS ONE</i> , 2011, 6, e28435.	1.1	56
32	Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study. <i>PLoS Medicine</i> , 2011, 8, e1001017.	3.9	251
33	7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?. <i>PLoS ONE</i> , 2011, 6, e26190.	1.1	52
34	Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. <i>BMC Infectious Diseases</i> , 2010, 10, 90.	1.3	73
35	Immunogenicity and Boosting After a Reduced Number of Doses of a Pneumococcal Conjugate Vaccine in Infants and Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 312-319.	1.1	141
36	Antibody Responses to Nasopharyngeal Carriage of <i>Streptococcus pneumoniae</i> in Adults: A Longitudinal Household Study. <i>Journal of Infectious Diseases</i> , 2005, 192, 387-393.	1.9	213